EFPIA Response to Tariffs: Concerns Over U.S.-E...

By HEOR Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. T...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditiona...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Econ...
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2...
FDA Approved Eye Drops: Lenz Therapeutics Launches VIZZ for Presbyopia Treatment
Enhancing Benefit Assessments: Insights from IQWiG Real-World Data Report
Donanemab Alzheimer’s Approval: A New Era in Treatment
Building a Better Ecosystem for Digitally Enabled Diabetes Care in Europe